Oncology Central

CD73–adenosine: a next-generation target in immuno-oncology

0

Cancer immunotherapy has entered in a new era with the development of first-generation immune checkpoint inhibitors targeting the PD1/PD-L1 and CTLA-4 pathways. In this context, considerable research effort is being deployed to find the next generation of cancer immunotherapeutics. The CD73–adenosine axis constitutes one of the most promising pathways in immuno-oncology.

To view restricted content, please:
Share:

Leave A Comment